Targets CD137 (4-1BB), a costimulatory molecule on activated T-cells. Urelumab enhances T-cell responses and is ideal for immune activation and cancer immunotherapy research.
Conditions générales
Garantie satisfait ou remboursé de 30 jours
Expédition : 2-3 jours ouvrables
